Our unique PDSP platform accelerates drug development.
BRIM accelerates drug development from preclinical to clinical proof of concept, targeting novel therapies for diseases with high unmet medical needs. Our projects are based on our proprietary Pigment Epithelium-Derived Factor (PEDF) derived Short Peptide (PDSP) platform, which can be applied across multiple therapy areas and indications.
Novel therapies for diseases with high unmet medical needs.
Our lead asset, BRM421, is on track to become a first-in-class treatment for Dry Eye Disease (DED) which treats and repairs corneal damage. BRM421 is currently in Phase II/III clinical trials. We are also developing new drugs to treat severe corneal damage (BRM423) and osteoarthritis (BRM521), both of which are developed from our PDSP platform.
I was impressed with BRIM’s innovation and the unique mechanism of action of their lead compound in treating Dry Eye Disease.Bob Ruffolo
BRIM Scientific Board Member and former president of R&D at Wyeth Pharmaceuticals
Going after remediating limbal cells is something that no one else is doing – it distinguishes BRIM from the rest of the marketDr. Eliot Lazar
KOL at BRIM and CEO at elCON Medical Consulting
If you can use a piece of peptide that achieves almost the function of a stem cell, I think that’s excitingDr. Wayne Liaw
Senior Fellow at BRIM and former Senior Director at Otonomy and Optimer